Navigation Links
Blueprint Medicines Appoints Jeffrey Albers as Chief Executive Officer
Date:7/24/2014

CAMBRIDGE, Mass., July 24, 2014 /PRNewswire/ -- Blueprint Medicines (Blueprint), a leader in discovering highly selective kinase inhibitors for genomically defined cancer patients, today announced the appointment of Jeffrey Albers as chief executive officer (CEO). Mr. Albers joins Blueprint from Algeta ASA, where he served on the executive management team as U.S. president prior to the acquisition by Bayer. Mr. Albers succeeds Alexis Borisy, co-founder and interim CEO of Blueprint and Partner at Third Rock Ventures, who will remain an active member of the Board of Directors.

"Jeff's demonstrated excellence in commercial preparation and execution, business development and team building will be invaluable as we continue to grow Blueprint and advance our pipeline of highly selective kinase drugs into clinical development and ultimately the market," said Daniel Lynch, executive chairman of Blueprint. "While we look ahead to the Company's next phase, the Blueprint Board would like to thank Alexis for his many contributions to Blueprint's successes."

Mr. Albers brings more than 20 years of experience as a life sciences executive with a track record of leading fully integrated organizations, successfully launching products and achieving aggressive revenue targets. At Algeta, Mr. Albers oversaw the commercial and business functions during a period of exponential growth in staff and revenue. Before Algeta, Mr. Albers spent seven years at Genzyme, where he served most recently as vice president of the U.S. hematology & oncology business unit. Mr. Albers holds a Masters of Business Administration and a Juris Doctor from Georgetown University. 

"Leading and growing the talented Blueprint team as we take two potential breakthrough product candidates into clinical trials while continuing to build a strong, sustainable pipeline is extremely exciting," said Mr. Albers. "I look forward to lending my experience from oncology and rare genetic diseases to accelerate Blueprint's progress toward discovering, developing and commercializing transformative medicines for genomically defined patients in need."

About Blueprint Medicines
Blueprint Medicines is a patient-driven oncology company developing highly selective kinase inhibitors for genomically defined cancer patients. Led by a management team and advisors with world-renowned expertise in cancer genomics, drug discovery and clinical oncology, Blueprint has developed a platform that combines genomics with a novel small molecule library of kinase inhibitors, enabling Blueprint to rapidly develop potent, highly selective compounds against clear genomic driver targets. Founded in 2011, Blueprint is privately held and initially backed by Third Rock Ventures and Fidelity BioSciences. For more information, please visit BlueprintMedicines.com.

CONTACT:
Investor Relations:
Beth DelGiacco
Stern Investor Relations, Inc.
212 362 1200
beth@sternir.com

Media Relations:
David Polk
Chandler Chicco Companies
310 309 1029
dpolk@chandlerchiccocompanies.com

Photo - http://photos.prnewswire.com/prnh/20140723/130038


'/>"/>
SOURCE Blueprint Medicines
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Worlds Only USDA Certified Organic and FDA Registered Homeopathic Medicines Guaranteed to Work
2. Lilly Expands Strategic Partnership with Chinese Manufacturer Novast to Serve Chinese Patients with High-Quality Branded Generic Medicines
3. Warning: Not All Cold Sore Medicines Are Created Equal
4. Kick Off Summer Vacation With Five Simple Tips to Safely Store Medicines While Traveling
5. Global pharmaceutical industry calls for broad-based cooperation to fight online sales of counterfeit medicines around the world
6. Unigene Provides Update Following Recent EMA Recommendation on Calcitonin-Containing Medicines
7. New Research Reveals Extent of Poor-Quality Antimalarial Medicines in South American Countries
8. Watson Applauds GPhA Study Demonstrating $1 Trillion in Prescription Drug Savings from Generic Medicines
9. Sigma-taus Antimalarial Awarded "Project of the Year" 2011 by Medicines for Malaria Venture
10. National Community Pharmacists Association and Purdue Pharma Urge Americans to Safeguard Rx Medicines This Holiday Season
11. PTC Therapeutics Announces European Medicines Agency Validation of Marketing Authorization Application for Ataluren in Duchenne Muscular Dystrophy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... Inc. announced today that its fully owned USA ... York City Office in Yonkers, New York ... (TWO 2 ) homecare therapy. This new East Coast location has ... under the company,s DMEPOS accreditation for Home/Durable Medical Equipment Services. ... Advanced Oxygen Therapy Inc. New ...
(Date:8/8/2017)... Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused on ... the second quarter ended June 30, 2017. ... to date: Continued ... lead project, BL-8040: Announced plans to ... stem cell mobilization treatment for autologous bone-marrow transplantation in ...
(Date:8/7/2017)... Diplomat Pharmacy, Inc. (NYSE: DPLO ) ... president, effective Aug. 7, 2017. ... other interests and will serve as president emeritus during a ... us in multiple leadership roles since he joined Diplomat with ... has provided decisive, strategic leadership which continues to benefit our ...
Breaking Medicine Technology:
(Date:8/22/2017)... ... August 22, 2017 , ... Although Labor Day is ... many communities have begun providing weekend displays, and numerous households celebrate the unofficial end ... can be downright terrifying for pets. , Kris Zambo, owner of Dynamite ...
(Date:8/21/2017)... ... August 22, 2017 , ... Nanoparticle research provides ... and safety. By learning and implementing best practices for containment using ventilated safety ... attendees will gain a better understanding of a method for safely testing nanotechnology ...
(Date:8/21/2017)... ... August 21, 2017 , ... Los Angeles area medical group ... academic year 2017-2018, Christina M. Busuito, M.D. and Lukasz Swistun, M.D. This one ... and Reconstructive Surgery. The candidate will have the opportunity to work with ...
(Date:8/21/2017)... ... August 21, 2017 , ... SportsEngine, Inc. , a ... Technology Partner of North Country Region Volleyball and will power registration, scheduling, and ... with providing sport management software to their member clubs. , SportsEngine ...
(Date:8/21/2017)... ... August 21, 2017 , ... ... place all over the country. , Outdoor running increases exposure to ultraviolet radiation, ... an increased risk of melanoma, and only half may be adequately protecting themselves ...
Breaking Medicine News(10 mins):